Farglitazar
Based on 1 Customer Validation
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.50%
- CAS. Nr.: 196808-45-4
- Formel: C34H30N2O5
- Molecular Weight:546.61
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CV-1 | EC50 |
0.34 nM
Compound: Farglitazar
|
Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.
Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.
|
[PMID: 11720854] |
| CV-1 | EC50 |
450 nM
Compound: Farglitazar
|
Maximal reporter activity against human Peroxisome proliferator activated receptor alpha Gal4 chimeric in transiently transfected CV-1 cells by functional assay.
Maximal reporter activity against human Peroxisome proliferator activated receptor alpha Gal4 chimeric in transiently transfected CV-1 cells by functional assay.
|
[PMID: 11720854] |
| HEK293 | EC50 |
0.321 μM
Compound: GI 262570
|
Agonist activity at PPARalpha receptor expressed in HEK293 cells by GAL4 transactivation assay
Agonist activity at PPARalpha receptor expressed in HEK293 cells by GAL4 transactivation assay
|
[PMID: 17292606] |
| HEK293 | EC50 |
0.0006 μM
Compound: GI 262570
|
Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay
Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay
|
[PMID: 17292606] |
| HEK293 | EC50 |
0.6 nM
Compound: GI 262570
|
Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay
Agonist activity at PPARgamma receptor expressed in HEK293 cells by GAL4 transactivation assay
|
[PMID: 17292606] |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 196808-45-4
-
Appearance Solid
-
Molecular Weight 546.61
-
Formel C34H30N2O5
-
Color White to yellow
-
SMILES
O=C(C1=CC=CC=C1)C2=C(C=CC=C2)N[C@H](C(O)=O)CC3=CC=C(C=C3)OCCC4=C(C)OC(C5=CC=CC=C5)=N4
-
Synonyms
GI262570; GI262570X
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (182.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (9.15 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8295 mL | 9.1473 mL | 18.2946 mL | 45.7364 mL |
| 5 mM | 0.3659 mL | 1.8295 mL | 3.6589 mL | 9.1473 mL | |
| 10 mM | 0.1829 mL | 0.9147 mL | 1.8295 mL | 4.5736 mL | |
| 15 mM | 0.1220 mL | 0.6098 mL | 1.2196 mL | 3.0491 mL | |
| 20 mM | 0.0915 mL | 0.4574 mL | 0.9147 mL | 2.2868 mL | |
| 25 mM | 0.0732 mL | 0.3659 mL | 0.7318 mL | 1.8295 mL | |
| 30 mM | 0.0610 mL | 0.3049 mL | 0.6098 mL | 1.5245 mL | |
| 40 mM | 0.0457 mL | 0.2287 mL | 0.4574 mL | 1.1434 mL | |
| 50 mM | 0.0366 mL | 0.1829 mL | 0.3659 mL | 0.9147 mL | |
| 60 mM | 0.0305 mL | 0.1525 mL | 0.3049 mL | 0.7623 mL | |
| 80 mM | 0.0229 mL | 0.1143 mL | 0.2287 mL | 0.5717 mL | |
| 100 mM | 0.0183 mL | 0.0915 mL | 0.1829 mL | 0.4574 mL |
Farglitazar Related Classifications
HY-105074 Related Classifications
Powered by Bioz